Cessatech A/S (CESSA)

Overview

Cessatech A/S is a pioneering company focused on addressing the critical gap in pediatric pain management through the development of innovative drug solutions in Denmark. Established in 2020 and headquartered in Copenhagen, the company dedicates its efforts to identify and develop drugs that cater to the unmet medical needs of children facing painful medical procedures. Cessatech A/S has strategically partnered with Ventis Pharma Corporation under a collaboration and license agreement, enhancing its capability to develop and formulate advanced pain management therapies. This move underscores the company's commitment to integrating cutting-edge science with patient needs, aiming to significantly improve the healthcare outcomes for the pediatric population.

Products and Services

Cessatech A/S has developed a specialized portfolio aimed at transforming pediatric pain management:

• CT001: An innovative analgesic nasal spray designed for children undergoing acute and planned painful procedures. This flagship product represents a significant advancement in non-invasive pain management techniques, offering a quick and effective method to alleviate pain without the need for injections.
• CT002: A nasal spray developed specifically for use during magnetic resonance imaging (MRI) scanning. Understanding the stress and discomfort children can experience during MRI procedures, CT002 aims to provide a sedative effect to ease the process, ensuring better compliance and results from diagnostic procedures.
• CT003: A local anesthetic gel formulated for the treatment of open wounds in children. Recognizing the necessity for immediate and effective pain relief in such scenarios, CT003 is designed to offer a soothing and pain-relieving effect when applied directly to wounds, thereby facilitating a more tolerable healing process for the young patients.